Early Experience of Helical Tomotherapy for Hepatobiliary Radiotherapy
Helical tomotherapy (HT), an image-guided, intensity-modulated, radiation therapy technique, allows for precise targeting while sparing normal tissues. We retrospectively assessed the feasibility and tolerance of the hepatobiliary HT in 9 patients. A total dose of 54 to 60 Gy was prescribed (1.8 or...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Case Reports in Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2011/545267 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850172836899979264 |
|---|---|
| author | Carole Massabeau Virginie Marchand Sofia Zefkili Vincent Servois François Campana Philippe Giraud |
| author_facet | Carole Massabeau Virginie Marchand Sofia Zefkili Vincent Servois François Campana Philippe Giraud |
| author_sort | Carole Massabeau |
| collection | DOAJ |
| description | Helical tomotherapy (HT), an image-guided, intensity-modulated, radiation therapy technique, allows for precise targeting while sparing normal tissues. We retrospectively assessed the feasibility and tolerance of the hepatobiliary HT in 9 patients. A total dose of 54 to 60 Gy was prescribed (1.8 or 2 Gy per fraction) with concurrent capecitabine for 7 patients. There were 1 hepatocarcinoma, 3 cholangiocarcinoma, 4 liver metastatic patients, and 1 pancreatic adenocarcinoma. All but one patient received previous therapies (chemotherapy, liver radiofrequency, and/or surgery). The median doses delivered to the normal liver and to the right kidney were 15.7 Gy and 4.4 Gy, respectively, below the recommended limits for all patients. Most of the treatment-related adverse events were transient and mild in severity. With a median followup of 12 months, no significant late toxicity was noted. Our results suggested that HT could be safely incorporated into the multidisciplinary treatment of hepatobiliary or pancreatic malignant disease. |
| format | Article |
| id | doaj-art-d514f2680ed7478dba856679fb2c3e03 |
| institution | OA Journals |
| issn | 2090-6587 2090-6595 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hepatology |
| spelling | doaj-art-d514f2680ed7478dba856679fb2c3e032025-08-20T02:19:58ZengWileyCase Reports in Hepatology2090-65872090-65952011-01-01201110.1155/2011/545267545267Early Experience of Helical Tomotherapy for Hepatobiliary RadiotherapyCarole Massabeau0Virginie Marchand1Sofia Zefkili2Vincent Servois3François Campana4Philippe Giraud5Department of Radiation Oncology and Medical Physics, Institut Curie, 75005 Paris, FranceDepartment of Radiation Oncology and Medical Physics, Institut Curie, 75005 Paris, FranceDepartment of Radiation Oncology and Medical Physics, Institut Curie, 75005 Paris, FranceDepartment of Radiology, Institut Curie, 75005 Paris, FranceDepartment of Radiation Oncology and Medical Physics, Institut Curie, 75005 Paris, FranceDepartment of Radiation Oncology and Medical Physics, Institut Curie, 75005 Paris, FranceHelical tomotherapy (HT), an image-guided, intensity-modulated, radiation therapy technique, allows for precise targeting while sparing normal tissues. We retrospectively assessed the feasibility and tolerance of the hepatobiliary HT in 9 patients. A total dose of 54 to 60 Gy was prescribed (1.8 or 2 Gy per fraction) with concurrent capecitabine for 7 patients. There were 1 hepatocarcinoma, 3 cholangiocarcinoma, 4 liver metastatic patients, and 1 pancreatic adenocarcinoma. All but one patient received previous therapies (chemotherapy, liver radiofrequency, and/or surgery). The median doses delivered to the normal liver and to the right kidney were 15.7 Gy and 4.4 Gy, respectively, below the recommended limits for all patients. Most of the treatment-related adverse events were transient and mild in severity. With a median followup of 12 months, no significant late toxicity was noted. Our results suggested that HT could be safely incorporated into the multidisciplinary treatment of hepatobiliary or pancreatic malignant disease.http://dx.doi.org/10.1155/2011/545267 |
| spellingShingle | Carole Massabeau Virginie Marchand Sofia Zefkili Vincent Servois François Campana Philippe Giraud Early Experience of Helical Tomotherapy for Hepatobiliary Radiotherapy Case Reports in Hepatology |
| title | Early Experience of Helical Tomotherapy for Hepatobiliary Radiotherapy |
| title_full | Early Experience of Helical Tomotherapy for Hepatobiliary Radiotherapy |
| title_fullStr | Early Experience of Helical Tomotherapy for Hepatobiliary Radiotherapy |
| title_full_unstemmed | Early Experience of Helical Tomotherapy for Hepatobiliary Radiotherapy |
| title_short | Early Experience of Helical Tomotherapy for Hepatobiliary Radiotherapy |
| title_sort | early experience of helical tomotherapy for hepatobiliary radiotherapy |
| url | http://dx.doi.org/10.1155/2011/545267 |
| work_keys_str_mv | AT carolemassabeau earlyexperienceofhelicaltomotherapyforhepatobiliaryradiotherapy AT virginiemarchand earlyexperienceofhelicaltomotherapyforhepatobiliaryradiotherapy AT sofiazefkili earlyexperienceofhelicaltomotherapyforhepatobiliaryradiotherapy AT vincentservois earlyexperienceofhelicaltomotherapyforhepatobiliaryradiotherapy AT francoiscampana earlyexperienceofhelicaltomotherapyforhepatobiliaryradiotherapy AT philippegiraud earlyexperienceofhelicaltomotherapyforhepatobiliaryradiotherapy |